STOCK TITAN

Immunic Q3 2026 net loss widens to $42.3M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Immunic, Inc. (IMUX) reported a third-quarter net loss of $42.3 million, compared with $25.6 million a year earlier, as operating expenses rose to $43.4 million from $26.0 million. Research and development expenses were $23.9 million versus $20.0 million, while general and administrative expenses were $19.4 million versus $6.0 million. Cash and cash equivalents were $132.0 million as of September 30, 2026; based on its current operating plan, the company expects these funds to support operations into late 2027.

The fully enrolled Phase 3 ENSURE-1 and ENSURE-2 trials randomized 1,121 and 1,100 patients, respectively, and top-line data are expected in December 2026. If results are positive, Immunic plans a U.S. New Drug Application submission in mid-2027, with a targeted potential approval date in 2028. Initiation of the Phase 3 PROTECT-MS trial is ongoing, with first-patient enrollment expected in the first half of 2027. The company reported exploratory and post-hoc CALLIPER analyses with stated limitations; vidofludimus calcium remains investigational and has not been approved.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Moderate pointThird-quarter net loss rose to $42.3 million from $25.6 million.

Filing Explained

The 8-K reports 15,880,822 common shares issued and outstanding at September 30, 2026, versus 12,038,263 at December 31, 2025. The larger share base means an unchanged holding represents a smaller fraction of Immunic.

Item 2.02 Results of Operations and Financial Condition Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Third-quarter net loss $42.3 million Three months ended September 30, 2026; compared with $25.6 million in the same period of 2025.
Third-quarter operating expenses $43.4 million Three months ended September 30, 2026; compared with $26.0 million in the same period of 2025.
Third-quarter research and development expenses $23.9 million Three months ended September 30, 2026; compared with $20.0 million in the same period of 2025.
Third-quarter general and administrative expenses $19.4 million Three months ended September 30, 2026; compared with $6.0 million in the same period of 2025.
Cash and cash equivalents $132.0 million As of September 30, 2026; expected to fund operations into late 2027 based on the current operating plan.
ENSURE-1 patients randomized 1,121 patients Phase 3 relapsing multiple sclerosis trial.
ENSURE-2 patients randomized 1,100 patients Phase 3 relapsing multiple sclerosis trial.
top-line data medical
"top-line data from the twin Phase 3 ENSURE trials"
New Drug Application (NDA) regulatory
"potential New Drug Application (NDA) submission in relapsing MS"
A new drug application (NDA) is a formal request submitted to regulatory authorities to gain approval for a new medication to be sold and used by the public. It is a comprehensive review process that examines the drug’s safety, effectiveness, and manufacturing quality. For investors, an NDA approval can signal a potential breakthrough product and influence a company's stock value.
open-label extension (OLE) medical
"during the open-label extension (OLE) phase"
An open-label extension (OLE) is a follow-up phase of a clinical trial where participants and researchers know the treatment being given, often after an initial blinded study. It allows for continued access to a promising therapy and provides additional safety and effectiveness data. For investors, it can signal ongoing interest in a treatment’s potential and help assess long-term benefits and risks.
post-hoc analysis medical
"In a post-hoc analysis applying two proposed novel statistical methods"
Post-hoc analysis is an examination of data carried out after an experiment, trial, or reporting period to look for patterns or explanations that were not specified beforehand. It matters to investors because such findings can suggest new opportunities or risks but are more likely to be chance results than preplanned conclusions, so they require independent confirmation before being treated as reliable — like noticing a pattern on a map after a trip and then testing it on the next journey.
Nurr1 medical
"vidofludimus calcium promoted neuronal survival under apoptotic stress conditions, an effect requiring Nurr1"
Nurr1 is a protein found in brain cells that acts like a light switch, turning on the genes needed for the creation and survival of dopamine-producing neurons. Investors care about Nurr1 because drugs that affect it are being explored as potential treatments for neurodegenerative and psychiatric conditions; progress or setbacks in that research can change a drug candidate's value, affect regulatory approval odds, and influence company valuations.
dihydroorotate dehydrogenase (DHODH) medical
"selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH)"
Dihydroorotate dehydrogenase (DHODH) is an enzyme inside cells that helps make the chemical building blocks needed for DNA and RNA. Investors care because drugs that block DHODH can slow rapidly dividing cells or modulate the immune system, making it a common target for cancer, autoimmune and antiviral therapies; progress in clinical trials, regulatory decisions, patents or competition around DHODH inhibitors can significantly affect a biotech’s risk and value.
Net loss $42.3 million Compared with $25.6 million in the third quarter of 2025.
Operating expenses $43.4 million Compared with $26.0 million in the third quarter of 2025.
Research and development expenses $23.9 million Compared with $20.0 million in the third quarter of 2025.
General and administrative expenses $19.4 million Compared with $6.0 million in the third quarter of 2025.
Net loss per basic and diluted share $0.99 Compared with $1.32 in the third quarter of 2025.
Guidance

Based on its current operating plan, cash and cash equivalents are expected to fund operations into late 2027; ENSURE trial top-line data are expected in December 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was IMUX's third-quarter 2026 net loss?

Immunic reported a net loss of $42.3 million for the three months ended September 30, 2026, compared with $25.6 million for the same period in 2025. Net loss per basic and diluted share was $0.99, versus $1.32.

When are IMUX's Phase 3 ENSURE results expected?

Top-line data from the twin Phase 3 ENSURE-1 and ENSURE-2 trials are expected in December 2026. If results are positive, Immunic plans to submit a U.S. New Drug Application in mid-2027, with a targeted potential regulatory approval date in 2028.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001280776 0001280776 2026-11-13 2026-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 13, 2026

 

IMMUNIC, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-36201   56-2358443

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

 

1200 Avenue of the Americas, Suite 200

New York, NY 10036

USA

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (332) 255-9818

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock, par value $0.0001   IMUX   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐ No ☐

 

 

 

 
 

 

Item 2.02. Results of Operations and Financial Condition

 

On November 13, 2026, Immunic, Inc. (the “Company”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s financial results for the quarter ended September 30, 2026, and providing a corporate update (the “Earnings Release”).

 

The information contained in Item 2.02 of this Current Report on Form 8-K, including the Earnings Release, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, this information shall not be deemed incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission, except as shall be expressly set forth by specific reference in any such filing.

 

Item 9.01. Financial Statements and Exhibits

 

Exhibit   Description
99.1   Press Release dated November 13, 2026.
104   Cover Page to this Current Report on Form 8-K in Inline XBRL.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

Dated: November 13, 2026 Immunic, Inc.
     
By: /s/ Erik Lundgren
    Erik Lundgren
    Chief Executive Officer

 

 

 

 

Exhibit 99.1

 

 

Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update

 

– Pivotal Phase 3 ENSURE-1 and ENSURE-2 Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis Remain on Track, with Top-Line Data Expected in December 2026 –

 

– Initiation of Phase 3 PROTECT-MS Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Ongoing, with First-Patient-Enrolled Expected in the First Half of 2027 –

 

– Executive Leadership Team Further Strengthened with Appointments of Chief Data and Digital Officer and Chief People Officer to Support Regulatory and Commercial Readiness –

 

NEW YORK, November 13, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.

 

“As we approach the top-line data from our Phase 3 ENSURE trials in relapsing multiple sclerosis (MS) in December, we believe Immunic is entering one of the most important periods in its history,” said Erik Lundgren, Chief Executive Officer of Immunic. “We are evolving from a science-driven biotechnology company into a fully integrated commercial organization, with a key focus on understanding and addressing the needs of people living with MS. We believe vidofludimus calcium has the potential to address mechanisms associated with both the neurodegenerative and inflammatory drivers of the disease, which, if confirmed in our Phase 3 trials, could offer a differentiated treatment option in MS. Subject to positive ENSURE results, we are preparing for a potential New Drug Application (NDA) submission in relapsing MS, while we continue to advance our Phase 3 program in progressive MS.”

 

“We were fortunate to present exciting data in four posters at MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting, which added complementary clinical and mechanistic evidence supporting the potential of vidofludimus calcium to address existing unmet needs in MS,” added Michael A. Panzara, M.D., M.P.H., Chief Medical Officer of Immunic. “Further, our Phase 3 ENSURE trials in relapsing MS continue to be on track to report top-line data in December 2026. Our teams remain focused on this readout and readiness for a potential NDA submission should the results be positive. In parallel, the Phase 2 CALLIPER data along with the insights shared by leading MS experts at our two recent R&D Days support the rational for our Phase 3 PROTECT-MS trial in progressive MS, with initiation ongoing and first-patient-enrolled expected in the first half of 2027.”

 

Third Quarter 2026 and Subsequent Highlights

 

●Ongoing Phase 3 ENSURE Relapsing MS Program: Continued to execute the fully enrolled twin Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing MS, which randomized 1,121 and 1,100 patients, respectively, at more than 100 sites in 15 countries.
●Preparation of Phase 3 Progressive MS Program: Continued initiation activities for the Phase 3 PROTECT-MS trial in progressive MS, informed by the Phase 2 CALLIPER trial data.

 

 

 

 

 

●Hosted Virtual Progressive MS R&D Day: On November 5, 2026, hosted a virtual R&D day focused on progressive MS. Jiwon Oh, M.D., Ph.D., FRCPC, Division of Neurology, University of Toronto, and Maria Pia Sormani, Ph.D., University of Genoa, Italy, joined Immunic’s management team to discuss the key unmet needs in progressive MS and the persistent needs for innovative approaches to the development of therapies that target novel mechanisms associated with neurodegeneration and MS progression. The event highlighted the potential expansion opportunity for vidofludimus calcium in progressive MS, including the clinical and scientific rationale supporting Immunic’s plans to initiate a Phase 3 progressive MS trial. A replay is available on the “Events and Presentations” section of Immunic’s website.
●New Data Presented at MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting: Presented new clinical, biomarker and preclinical data for vidofludimus calcium across four poster presentations at MSToronto2026, held October 21-23, 2026, in Toronto. Highlights included:

 

○New analyses of the Phase 2 CALLIPER trial in progressive MS showed that the favorable trends on disability outcomes observed during the double-blind main treatment period appeared to be maintained during the open-label extension (OLE) phase among participants who continued vidofludimus calcium treatment. Because the OLE phase is not placebo-controlled and includes only participants who elected to continue treatment, these results should be interpreted with caution. Only 6.5% of patients discontinued through the January 27, 2026 data cutoff, with a safety and tolerability profile that appeared consistent with that observed in the double-blind period.
○New preclinical findings suggest that vidofludimus calcium promoted neuronal survival under apoptotic stress conditions, an effect requiring Nurr1. Under these in vitro experimental conditions, this Nurr-1 dependent pro-survival effect was not observed with teriflunomide, providing preclinical evidence suggesting that it involves mechanisms beyond DHODH inhibition. The clinical relevance of these findings has not been established.
○An exploratory CALLIPER analysis found that vidofludimus calcium reduced Epstein-Barr virus (EBV)-specific T-cell receptor sequence matches versus placebo-treated patients, and, in a post-hoc analysis across all patients, reductions in EBV-specific matches were associated with improved Symbol Digit Modalities Test (SDMT) scores.
○In a post-hoc analysis applying two proposed novel statistical methods that integrate disability worsening and improvement into a single statistical measure, progressive MS patients in CALLIPER treated with vidofludimus calcium appeared more likely to have positive disability outcomes compared to placebo. These methods have not been validated or accepted by regulatory authorities.

 

●Hosted Virtual Relapsing MS R&D Day: On September 9, 2026, hosted a virtual R&D day focused on relapsing MS, at which management discussed the potential of vidofludimus calcium to address mechanisms associated with both neurodegenerative and inflammatory drivers of MS and shared insights into how its differentiated approach could add to the evolving treatment landscape in relapsing MS. MS experts Amit Bar-Or, M.D., FRCPC, Perelman School of Medicine, University of Pennsylvania, and Stephen Krieger, M.D., FAAN, Icahn School of Medicine, The Mount Sinai Hospital, provided expert perspectives on the MS patient journey, current treatment paradigms and unmet medical needs. A replay is available on the “Events and Presentations” section of Immunic’s website.

 

●Expansion of Executive Leadership Team and Board of Directors:

 

○Appointed Jaa Roberson as Chief People Officer, effective October 19, 2026. In this newly created executive role, Ms. Roberson leads Immunic’s global talent and organizational strategy as the company prepares for the ENSURE read-out and potential commercialization. Ms. Roberson brings more than two decades of human resources experience, most recently as Chief People Officer at Day One Biopharmaceuticals, and earlier, at Genentech supporting commercial franchises, including Ocrevus® for MS.

 

 

 

 

 

○Appointed Chitrang Davé, M.B.A., as Chief Data and Digital Officer, effective September 1, 2026. In this newly created C-suite role, Mr. Davé leads Immunic’s enterprise-wide data, analytics, AI and digital strategy in support of NDA and commercial readiness. Mr. Davé brings more than 25 years of data and analytics leadership experience across regulated life sciences environments, most recently as Head of Enterprise Data, AI & Advanced Analytics at Avidity Biosciences, and previously in senior roles at Edwards Lifesciences and Medtronic.
○Appointed Elena Ridloff, CFA, to the Board of Directors, effective August 6, 2026. Ms. Ridloff brings more than 20 years of leadership experience in finance, corporate development, investor relations, and capital markets across the biopharmaceutical industry. She currently serves as Chief Financial Officer and Chief Business Officer at Sionna Therapeutics.

 

Anticipated Clinical Milestones

 

●Vidofludimus Calcium in Relapsing MS: Top-line data from the twin Phase 3 ENSURE-1 and ENSURE-2 trials remains on track and is expected to be available in December 2026. If positive, Immunic plans to submit an NDA in the United States in mid-2027, with a targeted potential regulatory approval date in 2028.
●Vidofludimus Calcium in Progressive MS: The initiation of the Phase 3 PROTECT-MS trial in progressive MS is ongoing, with first-patient-enrolled expected in the first half of 2027.
●IMU-381: The IMU-381 program, selected to leverage the Nurr1 platform for neurologic and autoimmune diseases, continues to be in preclinical testing with lead candidate identification ongoing.

 

Financial and Operating Results

 

Total Operating Expenses for the three and nine months ended September 30, 2026 were $43.4 million and $111.9 million, respectively. Included in these results are $13.9 million and $25.2 million, respectively, of non-cash charges, primarily related to stock compensation expense.

 

Research and Development (R&D) Expenses were $23.9 million for the three months ended September 30, 2026, as compared to $20.0 million for the three months ended September 30, 2025. The $3.9 million increase reflects (i) a $1.9 million increase in personnel expenses, $0.6 million of which was related to non-cash stock compensation, (ii) a $1.4 million increase for vidofludimus calcium drug supply, (iii) a $2.9 million increase for NDA readiness activities, (iv) a $0.3 million increase due to drug-drug interaction studies in support of a potential NDA filing and (v) a $0.2 million increase related to costs across numerous categories, partially offset by (vi) a $1.8 million decrease related to the ENSURE clinical trials and (vii) a $1.0 million decrease related to the CALLIPER clinical trial.

 

For the nine months ended September 30, 2026, R&D expenses were $75.5 million, as compared to $62.9 million for the nine months ended September 30, 2025. The $12.6 million increase reflects (i) a $7.4 million increase in personnel expenses, $4.4 million of which was related to non-cash stock compensation, (ii) a $4.5 million increase for vidofludimus calcium drug supply, (iii) a $4.1 million increase for NDA readiness activities, (iv) a $3.9 million increase due to drug-drug interaction studies in support of a potential NDA filing and (v) a $1.7 million increase related to costs across numerous categories, partially offset by (vi) a $5.2 million decrease related to the ENSURE clinical trials and (vii) a $3.8 million decrease related to the CALLIPER clinical trial.

 

 

 

 

 

General and Administrative (G&A) Expenses were $19.4 million for the three months ended September 30, 2026, as compared to $6.0 million for the same period ended September 30, 2025. The $13.4 million increase was due to (i) an $11.0 million increase related to personnel expenses, of which $9.7 million was related to non-cash stock compensation primarily related to a separation agreement, (ii) a $1.3 million increase in legal and consultancy expenses, (iii) a $0.6 million increase in pre-commercial marketing expenses and (iv) a $0.5 million increase in related costs across numerous categories.

 

For the nine months ended September 30, 2026, G&A expenses were $36.4 million, as compared to $17.0 million for the same period ended September 30, 2025. The $19.4 million increase was due to (i) a $15.2 million increase related to personnel expenses, of which $13.2 million was related to non-cash stock compensation primarily related to a separation agreement, (ii) a $2.3 million increase in legal and consultancy expenses, (iii) a $1.2 million increase in pre-commercial marketing expenses and (iv) a $0.7 million increase in related costs across numerous categories.

 

Interest Income was $1.1 million for the three months ended September 30, 2026, as compared to $0.4 million for the three months ended September 30, 2025. The $0.7 million increase was due to a higher average cash balance as a result of the February 2026 Private Placement.

 

For the nine months ended September 30, 2026, interest income was $3.1 million, as compared to $0.8 million for the same period ended September 30, 2025. The $2.3 million increase was due to a higher average cash balance as a result of the February 2026 Private Placement.

 

Other Income (Expense) was ($0.03 million) for the three months ended September 30, 2026, as compared to ($0.01 million) for the same period ended September 30, 2025.

 

For the nine months ended September 30, 2026, Other Income (Expense) was ($0.2 million), as compared to $1.2 million for the same period ended September 30, 2025. The $1.4 million decrease was primarily attributable to (i) $1.0 million of grant income from the German Federal Ministry of Finance recognized in the first quarter of 2025 and no grant income in 2026 and (ii) a $0.4 million decrease across various categories.

 

Net Loss for the three months ended September 30, 2026, was approximately $42.3 million, or $0.99 per basic and diluted share, based on 42,797,370 weighted-average common shares outstanding, compared to a net loss of approximately $25.6 million, or $1.32 per basic and diluted share, based on 19,389,776 weighted-average common shares outstanding for the same period ended September 30, 2025.

 

Net loss for the nine months ended September 30, 2026, was approximately $109.0 million, or $2.83 per basic and diluted share, based on 38,508,964 weighted-average common shares outstanding, compared to a net loss of approximately $77.9 million, or $5.45 per basic and diluted share, based on 14,281,149 weighted-average common shares outstanding for the same period ended September 30, 2025.

 

Cash and Cash Equivalents as of September 30, 2026 were $132.0 million. Based on its current operating plan, Immunic expects that these funds will be sufficient to fund its operations into late 2027.

 

 

 

 

 

About Immunic, Inc.

 

Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company’s lead investigational asset, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials in relapsing multiple sclerosis, with top-line data expected to be available in December 2026. Initiation of an additional Phase 3 clinical trial in progressive multiple sclerosis is ongoing, with first-patient-enrolled expected in the first half of 2027. Vidofludimus calcium combines potential neuroprotective effects associated with nuclear receptor-related 1 (Nurr1) activation with anti-inflammatory and anti-viral effects associated with selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH). The company’s development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases. For further information, please visit: www.imux.com.

 

Vidofludimus calcium (IMU-838) is an investigational medicinal product that has not been approved or authorized by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other regulatory authority for any indication in any jurisdiction. Its safety and efficacy have not been established. Any clinical, biomarker, or preclinical findings described reflect investigational data and are not intended to suggest that vidofludimus calcium is safe or effective for any use.

 

Cautionary Statement Regarding Forward-Looking Statements

 

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the nature, strategy and focus of the company; the development and commercial potential of Immunic’s product candidates, including their potential to safely and effectively target diseases; preclinical and clinical data for Immunic’s development programs; the expected timing and results of the Phase 3 ENSURE trials; the timing of a Phase 3 trial of vidofludimus calcium in progressive multiple sclerosis; the timing of potential NDA submission and regulatory approval; expectations regarding the capitalization, resources and ownership structure of the company; the expected sufficiency of Immunic’s cash and cash equivalents; and the executive and board structure of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risk that top-line results from the ENSURE-1 and ENSURE-2 trials may be delayed, negative, or fail to meet their primary or secondary endpoints; the risk that results of earlier, post-hoc, exploratory, open-label or preclinical analyses may not be predictive of, or confirmed in, subsequent controlled clinical trials or accepted by regulatory authorities; the risk that the initiation, or first-patient enrollment in, of the Phase 3 progressive MS trial, or the submission or approval of an NDA, may be delayed or may not occur; risks related to drug development and the regulatory review process; the risk that Immunic’s cash and cash equivalents may be insufficient to fund operations for the period anticipated, including due to changes to its operating plan, and Immunic’s need to raise additional capital; increasing inflation, tariffs and macroeconomic trends; impacts of the Ukraine – Russia conflict and the conflict in the Middle East on clinical trials; changes to the size of the target markets for the company’s product candidates; the protection and market exclusivity provided by Immunic’s intellectual property; and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company’s subsequent filings with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.

 

Contact Information

 

Immunic, Inc.

 

Jessica Breu

Vice President Investor Relations and Communications

+49 89 2080 477 09

jessica.breu@imux.com

 

US IR Contact

 

LifeSci Advisors

Joyce Allaire

immunic@lifesciadvisors.com

 

US Media Contact

 

Real Chemistry

media@imux.com

 

 

 

 

 

Financials

 

Immunic, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

(Unaudited)

 

  

September 30,

2026

 

December 31,

2025

   (Unaudited)   
Assets          
Current assets:          
Cash and cash equivalents  $131,963   $15,483 
Other current assets and prepaid expenses   3,124    7,386 
Total current assets   135,087    22,869 
Property and equipment, net   832    608 
Right-of-use assets, net   504    575 
Total assets  $136,423   $24,052 
Liabilities and Stockholders’ Equity          
Current liabilities:          
Accounts payable  $10,120   $10,138 
Accrued expenses   20,058    18,645 
Other current liabilities   1,372    1,835 
Total current liabilities   31,550    30,618 
Long-term liabilities          
Other long term liabilities   400    107 
Total long-term liabilities   400    107 
Total liabilities   31,950    30,725 
Commitments and contingencies          
Stockholders’ equity:          
Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding as of September 30, 2026 and December 31, 2025   —      —   
Common stock, $0.0001 par value; 500,000,000  authorized as of September 30, 2026 and December 31, 2025, and 15,880,822 and 12,038,263 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively   1    1 
Additional paid-in capital   819,290    599,249 
Accumulated other comprehensive income   2,749    2,648 
Accumulated deficit   (717,567)   (608,571)
Total stockholders’ equity   104,473    (6,673)
Total liabilities and stockholders’ equity  $136,423   $24,052 

 

 

 

 

 

Immunic, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

(Unaudited)

 

  

Three Months

Ended September 30,

 

Nine Months

Ended September 30,

   2026  2025  2026  2025
Operating expenses:                    
Research and development  $23,948   $20,012   $75,505   $62,914 
General and administrative   19,421    5,981    36,426    16,987 
Total operating expenses   43,369    25,993    111,931    79,901 
Loss from operations   (43,369)   (25,993)   (111,931)   (79,901)
Other income (expense):                    
Interest income   1,093    419    3,139    843 
Other  income (expense), net   (33)   (5)   (204)   1,186 
Total other income   1,060    414    2,935    2,029 
Net loss  $(42,309)  $(25,579)  $(108,996)  $(77,872)
                     
Net loss per share, basic and diluted  $(0.99)  $(1.32)  $(2.83)  $(5.45)
                     
Weighted-average common shares outstanding, basic and diluted   42,797,370    19,389,776    38,508,964    14,281,149 

 

 

 

Filing Exhibits & Attachments

5 documents

Keep reading